S. Karumanchi

A Time‐to‐Event Exposure‐Response Model for Amyloid‐Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease

I. Nestorov, K. Kowalski, S. Chapel, 2022, Journal of clinical pharmacology.

A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.

A. Yates, V. C. Karumanchi, S. Karumanchi, 1992, The Journal of clinical psychiatry.

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

R. Motzer, T. Powles, T. Choueiri, 2021 .